A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia. Background: Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results